deltatrials
Completed PHASE1 NCT01217177

A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer

Sponsor: Novartis Pharmaceuticals

Conditions Locally Advanced Cervical Cancer
Interventions everolimus
Updated 5 times since 2017 Last updated: Apr 1, 2015 Started: Dec 31, 2011 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

Listed as NCT01217177, this PHASE1 trial focuses on Locally Advanced Cervical Cancer and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rio de Janeiro, Brazil